Modamide

Quick links to important sections

Modamide

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Modamide

Property Description
Active ingredient Amiloride Hydrochloride
Form Tablet (Oral Dosage Form)
Pharmacological class Potassium-sparing Diuretic
General purpose Fluid balance and blood pressure support
Origin Synthetic (Pyrazine Compound)

What Type of Medicine is Modamide (Amiloride)?

Modamide is a pharmaceutical preparation whose active ingredient is Amiloride Hydrochloride, a substance considered an essential medicine. This compound is chemically derived as a synthetic pyrazine compound and is categorized primarily as an antikaliuretic-diuretic agent, belonging to the functional group known as potassium-sparing diuretics. Within the broader system of drug classification, it is established as an antihypertensive agent. The drug's key feature is its capacity to increase the volume of urine output while conserving essential potassium, mitigating the risk of hypokalemia, a common consequence seen with some other classes of water-removal medication.

Composition and General Purpose of This Diuretic

The medicine is supplied as an oral dosage form, specifically a tablet, intended for systemic absorption via the oral route. The drug’s core purpose is to serve as a focused tool for volume control, assisting the body in the necessary excretion of excess sodium and water. It achieves this by acting as an ENaC channel inhibitor, blocking specific epithelial sodium channels in the kidney, which is the specialized mechanism of effect responsible for preserving potassium. This medicine helps the body manage extra fluid and salt. Its primary general benefit is facilitating effective fluid removal and contributing to blood pressure management while reliably safeguarding the patient from detrimental electrolyte depletion.

Regulatory References

  1. NIH Drug Information

What side effects are possible with Modamide?

Official Safety Profile of Modamide (Amiloride Hydrochloride)

The official safety profile for Modamide, whose active ingredient is Amiloride Hydrochloride, is defined by classifications found in governmental regulatory documents and clinical trials, focusing on adverse reactions and specific usage limitations.

Key Safety Classifications

Classification Area Regulatory Description
Primary Serious Risk Hyperkalemia (elevated plasma potassium levels > 5.5 mEq/L) is identified in regulatory texts as the most serious, potentially fatal risk.
Common Adverse Reactions Reactions frequently documented include headache, fatigue, weakness, dizziness, and nausea. These effects are generally classified as common in clinical studies.
Affected Organ Systems Adverse reactions are classified by System-Organ Class (SOC) categories, including Metabolism and Nutrition Disorders, Gastrointestinal Disorders, Nervous System Disorders, and Cardiac Disorders.
Safety Restrictions The medicine is contraindicated in patients with pre-existing hyperkalemia or evidence of impaired renal function. Co-administration with potassium supplements or other potassium-sparing agents is generally restricted.

Population and Exposure-Related Safety Notes

The regulatory profile specifies that the risk of hyperkalemia is heightened in certain populations, notably patients with renal impairment or diabetes mellitus. Use requires caution in older adults due to the higher likelihood of decreased organ function. Furthermore, official documentation notes that signs of orthostatic hypotension (dizziness or lightheadedness upon standing) may be more common when treatment is initiated.

The entirety of the safety profile is structured to emphasize the necessity of managing electrolyte stability, establishing clear limitations on use based on the patient’s existing kidney function and potassium status.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information for products containing Modamide often indicates that human overdose data are limited or nonexistent. However, based on the known pharmacological class, an overdose is anticipated to result in an exaggeration of the drug's primary effects, leading to potentially serious physiological imbalances.

Overdose Manifestations
The most likely documented signs in an overdose are dehydration and severe electrolyte imbalance (such as profound hyperkalemia).
Severe symptoms that require immediate attention may include irregular heartbeats, muscle weakness, numbness, and decreased level of consciousness.
Emergency Actions and When to Seek Help
Seek emergency medical attention immediately for any suspected overdose. This includes calling emergency services or a national Poison Control Center, even if no symptoms are present.
The general management for an overdose involves supportive measures. This includes establishing a patent airway and continuously monitoring vital signs, fluid balance, and serum electrolyte levels.
Due to the risk of severe hyperkalemia, specific interventions may focus on promptly correcting high potassium levels. Treatment is primarily symptomatic and supportive until the drug is eliminated from the system.

Therapeutic Uses of Modamide


What Modamide Treats: Main Uses and Benefits

The medication is commonly used across conditions presenting with systemic fluid imbalance, primarily for managing hypertension (high blood pressure) and edematous states associated with chronic heart failure or liver conditions. It is frequently applied in clinical settings that involve acute or unstable symptom patterns, especially when other kaliuretic-diuretic agents are part of the treatment plan.

The therapeutic benefit may be to provide support for necessary fluid removal—which helps ease symptoms related to physical discomfort like swelling (edema)—while simultaneously contributing to the management of potassium levels. This combination may assist with easing challenging symptoms and addressing the potential risk of hypokalemia, which supports general well-being during symptomatic phases.

“The therapeutic focus is to provide supportive relief that helps patients cope more steadily with difficult episodes of fluid retention while supporting the management of internal electrolyte stability.”


Quick Fact: Relief for Systemic Imbalance Modamide is utilized for easing symptoms that create noticeable physiological strain by offering support in supporting the management of electrolyte balance during aggressive fluid management.

Regulatory References

  1. NIH MedlinePlus overview of Amiloride

Eligibility and Restrictions for Use

Modamide's official eligibility profile is defined by regulatory documents based primarily on the patient’s potassium and renal status.

Eligibility Status Population or Condition
Contraindicated (Must Not Use) Hyperkalemia (serum potassium ge 5.5 mEq/L)
Concurrent use of other potassium-sparing diuretics or potassium supplements (including salt substitutes).
Severe Renal Impairment: Anuria (no urine production), Acute or Chronic Renal Insufficiency, or documented Diabetic Nephropathy.
Known Hypersensitivity to the active ingredient.
Restricted/Conditional Use Diabetes Mellitus: Use should be avoided if possible; if used, frequent and careful monitoring of serum electrolytes and renal function is mandatory due to a high risk of hyperkalemia.
Geriatric Patients: Use requires caution, as older adults face an increased hyperkalemia risk and may have reduced renal function, necessitating careful oversight.
Pregnancy: Use is permissible only if clearly needed.
Lactation: Use is not recommended; a decision must be made to discontinue nursing or the drug.
Use Not Established Pediatric Patients (under 18 years): Safety and effectiveness have not been established.

The restrictions emphasize the necessity of maintaining stable potassium levels. The conditional use requirements ensure that high-risk groups, such as the elderly and those with kidney function impairment, receive continuous, careful monitoring.

What should I know about interactions with other medicines?

Modamide Interactions with Other Medicines and Products

Modamide's (Amiloride Hydrochloride) interaction profile is defined by its effects on potassium and fluid balance, as detailed in official regulatory documents. This section summarizes documented interaction patterns without providing clinical advice or dosing instructions.


Formally Contraindicated Combinations

Regulatory information strictly contraindicates combining Modamide with other potassium-sparing diuretics (such as Spironolactone and Triamterene) or routine potassium supplements and potassium-containing salt substitutes. These combinations significantly increase the documented risk of severe hyperkalemia (high serum potassium).

Pharmacodynamic Interactions

  • Hyperkalemia Risk: The risk of elevated serum potassium is significantly increased when Modamide is co-administered with ACE Inhibitors or Angiotensin II Receptor Blockers (ARBs), and with certain immunosuppressants (e.g., Cyclosporine). Close monitoring is required.
  • Reduced Efficacy: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may reduce Modamide's effectiveness in controlling blood pressure and fluid retention, while also increasing hyperkalemia risk.
  • Toxicity: Modamide reduces the renal clearance of Lithium, which can lead to dangerously high Lithium plasma levels and documented toxicity.
  • Enhanced Hypotension: The blood pressure lowering effect may be potentiated by alcohol or co-administered antihypertensives.

Procedural and Population Constraints

Official labeling states that Modamide must be discontinued at least three days before specific glucose tolerance tests. Caution is also noted for elderly patients using NSAIDs and for patients with Diabetes Mellitus due to a heightened risk of hyperkalemia.

Mechanism of Action

How Modamide Works

Modamide (Amiloride) functions as a targeted modifier of renal ion transport, with its action governed by two principal mechanistic domains that together produce its physiological profile.


Targeting the Epithelial Sodium Channel ( ENaC)

This domain covers the molecular target and interaction type where Modamide directly and reversibly blocks the Epithelial Sodium Channel ( ENaC) on the principal cells of the collecting duct. This primary action prevents the normal final reabsorption of sodium ions ( Na^+) from the urine, initiating the entire mechanism.


Modulating the Electrical Driving Force for Potassium

This domain addresses the mechanistic cascade and the resulting physiological consequence. By halting the flow of positive sodium charge through ENaC, the drug abolishes the lumen-negative potential that naturally forms in the tubule. This removal of the electrical gradient directly suppresses the passive secretion of potassium ( K^+) and hydrogen ( H^+) ions, a process that results in potassium conservation ( K^+ sparing) and an increase in water excretion.

Dosage and Administration Information

How to Use Modamide: Administration Guidelines

Modamide is administered via the oral route as a tablet and is predominantly utilized as adjunctive therapy alongside kaliuretic diuretics. Established protocols establish the typical adult starting dose at 5 mg once daily, with the regimen often initiating in this manner regardless of the specific indication. The usual maintenance dose subsequently ranges from 5 mg to 10 mg daily, which may be adjusted to meet the therapeutic objective. The maximum daily dose is 20 mg.

The medicine is typically taken once daily, although administration in two divided doses is practiced. It is instructed that the tablets should be consumed with food to facilitate consistent intake. When used concurrently with other diuretics, Modamide should be taken at the same time as the co-administered medication.

Specific population-based use rules are established for this medication. For instance, in adults with specific levels of renal impairment (defined by creatinine clearance), the dose must be reduced by 50% to prevent accumulation. Use in the pediatric population (under 18 years of age) is generally not recommended because efficacy and safety in this group have not been formally established. Furthermore, a specific procedural condition requires that Modamide be discontinued at least three days prior to a scheduled glucose tolerance test. These parameters outline the framework for administration.

Recent Clinical Evidence

Modamide: Recent Clinical Evidence

This overview describes the types of clinical research studies that have been conducted for Modamide (Amiloride), what the studies observed, and the known limits of the current evidence. It does not provide medical advice, dosing, or safety information.


Evidence for Use in Managing High Blood Pressure (Hypertension)

Research has explored Modamide for use in patients with high blood pressure, particularly in combination with thiazide diuretics. Randomized Controlled Trials (RCTs) monitored outcomes such as changes in blood pressure readings over defined time intervals. Long-term studies involving the combination regimen also described patterns in the frequency of major cardiovascular events. What remains uncertain is the full extent of the medicine’s activity when it was studied alone, as the research evidence primarily focuses on combination therapy.


Evidence for Use in Managing Fluid Retention (Edematous States)

Modamide was evaluated in research exploring systemic fluid retention (edema) associated with conditions like heart failure or specific kidney conditions. Studies often included small groups of patients and monitored outcomes related to physical discomfort and systemic imbalance, such as changes in body fluid volume. Pilot studies reported observed decreases in overhydration over short periods, which were comparable to findings for the evaluated standard treatments. However, the evidence in this area is generally limited and comes largely from trials where Modamide was observed in combination.


Research on Potassium Stabilization

The potassium-sparing activity of Modamide was evaluated in numerous controlled studies and RCTs. Research examined how this medicine affects serum potassium concentration when used alongside other diuretics. The research describes patterns where the addition of Modamide to a thiazide diuretic was associated with higher measured average serum potassium levels compared to thiazide use alone.


Evidence Limitations and Research Gaps

Research highlights several areas where certainty remains low or where data are still needed. Follow-up durations were limited in many studies, meaning long-term effects on metabolic or electrolyte effects are not fully established. Additionally, there is a lack of robust comparative evidence for Modamide as a monotherapy for high blood pressure. Data for certain groups, such as older adults with complex health needs or specific comorbidities, remains insufficient because many large trials exclude these patients.

Key Studies & References

  1. AMILORIDE HYDROCHLORIDE TABLETS, USP - Official FDA Label/DailyMed Monograph
  2. Amiloride - StatPearls (General Pharmacology and Indications Review)

Frequently Asked Questions (FAQ)

Common questions about Modamide (FAQ)


Q: What makes Modamide different from a standard diuretic like hydrochlorothiazide?

Modamide is officially classified as a potassium-sparing diuretic. Regulatory classification indicates Modamide acts to conserve potassium, which contrasts with many standard diuretics that promote potassium loss. Its mechanism involves increasing the removal of salt and water while helping to maintain the body's potassium levels.

Q: What should I know about alcohol consumption while taking Modamide?

Official information states that alcohol may enhance the blood pressure-lowering effect of Modamide. This enhancement can increase the risk of symptoms like dizziness or lightheadedness upon standing, known as orthostatic hypotension.

Q: Are there special considerations for older adults (seniors) taking Modamide?

Official labeling advises that Modamide should be used with caution in older adults. This is due to the higher likelihood of reduced kidney function, which increases the potential risk of hyperkalemia (high potassium levels). Due to the heightened risk profile, the official profile emphasizes the need for careful oversight and monitoring of electrolytes in this population.

Q: Is Modamide used for heart failure, and if so, how?

Modamide is indicated as an add-on treatment alongside other diuretics for managing fluid retention, or edema, associated with congestive heart failure. Its main role is to help prevent the excessive loss of potassium that often occurs when taking those other diuretic medications.

Q: Does Modamide require regular blood work or lab tests?

Yes, official prescribing information states that close monitoring of serum potassium levels and kidney function is essential due to the risks of hyperkalemia and impaired renal function. This is a critical safety measure outlined in the regulatory documents.

Q: What are the possible serious side effects of Modamide that require immediate medical attention?

The most serious risk identified in regulatory documents is hyperkalemia, or dangerously high potassium levels. Warning signs may include an irregular heartbeat, unusual tiredness, muscular weakness, or a strange tingling sensation. In addition, signs of a severe allergic reaction or extreme dehydration are noted as serious events.

Q: Can taking Modamide cause skin rashes or allergic reactions?

Yes, regulatory documents note that hypersensitivity (an allergic reaction) to the active ingredient is a contraindication. Skin rash is a symptom that has been reported as part of an allergic reaction to this medicine.

Q: What is the difference between Modamide and Spironolactone?

Both Modamide and Spironolactone are classified as potassium-sparing diuretics. However, they work differently: Modamide directly blocks the epithelial sodium channel ( ENaC), while Spironolactone works indirectly by blocking the action of the hormone aldosterone.

Q: What should be done if a dose of Modamide is missed?

Official patient instructions state that if a dose is missed, it can be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped entirely, and the medicine should not be doubled to compensate.

Q: Can Modamide be used as a monotherapy, or is it always combined with another drug?

Modamide is primarily indicated in regulatory labeling for use as an adjunctive (add-on) treatment alongside other diuretics. It is rarely used as a single agent because its diuretic effect is considered weak when used alone, and using it solo carries a heightened risk of hyperkalemia.

Q: Does Modamide interact with common supplements like magnesium or calcium?

Official information strictly contraindicates combining Modamide with potassium supplements. Regarding other minerals, Modamide has been shown to reduce the enhanced loss of magnesium that can be caused by other diuretics. Patients are generally advised to discuss all supplements, including magnesium and calcium, with their healthcare provider, as electrolyte balance is critical when taking this medication.

Q: Does Modamide affect cholesterol or triglyceride levels?

The safety profile includes adverse reactions categorized under metabolic disorders. However, unlike some other diuretic classes, regulatory documents do not consistently report a significant adverse effect of Modamide specifically on cholesterol or triglyceride levels.

Q: Is Modamide considered safe during pregnancy or while breastfeeding?

Official labeling restricts use during pregnancy, stating it should only be used if clearly needed. Use is not recommended while breastfeeding, and a decision must be made to either discontinue nursing or discontinue the medication.

Q: What is the expected onset of action for Modamide?

According to the drug's clinical pharmacology profile, the diuretic effect typically begins within two hours after the medicine is taken orally. The maximum effect on the excretion of electrolytes generally occurs within six to ten hours.

Q: How long does the effect of a single dose of Modamide typically last?

The effects of a single dose of Modamide on electrolyte excretion are generally reported in regulatory documents to last for approximately 24 hours.

Q: Is it normal to experience increased urination when starting Modamide?

Yes, as Modamide is a diuretic (a 'water pill'), an increase in the flow of urine is generally expected. Its purpose is to help the body remove excess salt and water.

Q: What signs or symptoms should I watch out for that might indicate high potassium?

Official warnings note that signs associated with high potassium levels (hyperkalemia) can include unexplained muscular weakness, fatigue, a tingling sensation in the hands or feet, and an irregular or slow heartbeat.

Q: Can Modamide cause digestive issues like nausea, vomiting, or stomach pain?

Yes, official documents report that nausea and abdominal or stomach pain are listed as common adverse reactions. Vomiting and a general loss of appetite have also been reported in patient studies.

Q: Is it common to feel unusually tired or weak when taking Modamide?

Fatigue and weakness are documented as common adverse reactions in the official safety profile. It is important to know that unusual tiredness or weakness can also be a warning sign of high potassium levels or another electrolyte imbalance.

Q: Can Modamide cause headaches or dizziness?

Yes, headaches and dizziness are reported in official documents as common adverse reactions experienced by people taking Modamide. Dizziness can be a sign of low blood pressure, especially when changing position quickly.

Q: Can lifestyle factors like diet (e.g., high-salt foods) affect how Modamide works?

Modamide is a medication intended to help control salt and fluid balance in the body. While the medicine is strictly contraindicated with potassium-containing salt substitutes, general dietary factors, particularly a high intake of regular salt, can influence the overall fluid and electrolyte balance the medicine is attempting to manage.

Q: Is Modamide used to treat or manage low potassium levels (hypokalemia)?

Yes, Modamide is specifically indicated as an adjunctive treatment for patients who develop hypokalemia (low potassium) while taking other diuretics. By conserving potassium, it helps the body restore and maintain normal serum potassium levels.

Q: Can Modamide cause vision changes or eye problems?

Vision changes, including blurred vision, have been reported in regulatory documents as less common adverse reactions that may occur with this medicine.

Q: Are there reports of Modamide causing sexual side effects like decreased libido or erectile dysfunction?

Yes, regulatory reports include decreased interest in sexual intercourse (libido) and inability to maintain an erection (impotence) as less common side effects reported during clinical use.

Q: Is it normal for Modamide to cause dry mouth or increased thirst?

Yes, dry mouth and increased thirst are listed as reported side effects. These symptoms are often associated with the medication’s effect on fluid balance or may indicate that an electrolyte imbalance is occurring.

Q: Is there a risk of dehydration when taking Modamide?

Yes, like all diuretics, Modamide is associated with fluid elimination. Regulatory warnings note that this can potentially lead to dehydration or electrolyte imbalance.

Q: Does Modamide affect the risk of gout attacks?

The official product information advises using Modamide with caution in patients who have a history of gout or high levels of uric acid in the blood (hyperuricemia). This caution is noted because the medicine may potentially worsen these conditions.

Q: Can Modamide cause symptoms like confusion or a strange tingling sensation (paresthesia)?

Yes, confusion and paresthesia, which is described as a tingling, burning, or numb feeling, are listed as reported adverse reactions. These symptoms can also be warning signs of a serious electrolyte imbalance like hyperkalemia.

How should Modamide be stored and disposed of?

Modamide (Amiloride Hydrochloride Tablets) must be stored strictly according to the conditions defined in the official regulatory labeling.

Storage Requirements

Item Official Regulatory Requirement
Temperature Store at Controlled Room Temperature (20°C to 25°C or 68°F to 77°F).
Handling Avoid freezing and excessive heat; temporary excursions up to 30°C (86°F) are permitted.
Protection Keep the medicine in its tightly closed container to protect it from moisture and humidity.
Child Safety Keep out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Disposal of any unused or expired Modamide must follow established regulatory protocols:

  • Discard the product according to local environmental guidelines and drug take-back programs.
  • It must not be flushed down a toilet or poured into a drain unless specifically authorized by official regulatory guidance for this product.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Modamide found in:

A-Z Index: